Vancomycin monitoring in children using bayesian estimation.

Area of Science:

• Pediatric pharmacology
• Clinical pharmacokinetics
• Therapeutic drug monitoring

Background:

• Optimal vancomycin monitoring in children requires evaluating exposure targets using area under the curve (AUC).
• Current monitoring strategies need assessment for accuracy and precision in pediatric populations.

Purpose of the Study:

• To compare the accuracy and precision of vancomycin AUC estimations using one versus two serum samples against a rich sampling method.
• To determine the performance of these strategies in predicting future AUC using a validation sample.

Main Methods:

• Retrospective cohort study utilizing population-based pharmacokinetic modeling with Bayesian estimations.
• Included pediatric subjects aged 3 months to 21 years receiving vancomycin with multiple serum samples.
• AUC estimations were evaluated using one-sample (1S) and two-sample (2S) strategies against rich (RS) and validation (VS) samples.

Main Results:

• Analysis included 138 pediatric subjects with 712 vancomycin serum concentrations.
• The two-sample (2S) strategy demonstrated improved accuracy (-2.0% vs -7.6%) and precision (10.3% vs 12.8%) for AUC estimations compared to the one-sample (1S) strategy against the rich sample (RS).
• The 2S strategy also showed improved accuracy and precision in predicting future AUC against the validation sample (VS).

Conclusions:

• The two-sample (2S) vancomycin sampling strategy enhances accuracy and precision for AUC estimation and prediction in children.
• Evaluating two drug concentrations is recommended for ensuring adequate vancomycin exposure in pediatric patients.